RCT Not RWE: Two Year Report Card For The Cancer Drugs Fund Reforms

October 4, 2018 Danielle Twigg

 The Cancer Drugs Fund (CDF) was set up in 2011 in England to enable patients to access oncology therapies that are not routinely publically funded. In April 2016, the CDF became a temporary reimbursement fund under the remit of NICE with the aim of collecting observational data to inform subsequent technology appraisals. This research aims to evaluate how the reformed CDF has been utilised in the two years since its implementation.

Authors: Sean Walsh, Lok Wan Liu, Richard Macaulay

To find out more about this poster you can register to download it here after the ISPOR event.

Previous Article
European Conditional Marketing Authorization – Does Early Marketing Authorization Translate Into Early Reimbursement And Patient Access?
European Conditional Marketing Authorization – Does Early Marketing Authorization Translate Into Early Reimbursement And Patient Access?

Next Article
NICE And The Cancer Drugs Fund – Can Observational Evidence Inform Funding Decisions In Oncology?
NICE And The Cancer Drugs Fund – Can Observational Evidence Inform Funding Decisions In Oncology?